Membrane cholesterol and the formation of cholesterol domains in the pathogenesis of cardiovascular disease

被引:5
作者
Troup, GM
Xie, Y
Boesze-Battaglia, K
Huang, Y
Kirk, T
Hanley, F
Tulenko, TN
机构
[1] Thomas Jefferson Univ, Coll Med, Dept Surg, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Coll Med, Dept Biochem, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Coll Med, Dept Mol Pharmacol, Philadelphia, PA 19107 USA
关键词
atherosclerosis; cardiac myocytes; endothelium; heart failure; smooth muscle;
D O I
10.1002/masy.200550104
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
At least three types of cholesterol-rich membrane domains have been described in biological membranes including cholesterol rafts, membrane caveolae and crystalline cholesterol domains,. While clear biological functions have been ascribed to both rafts and caveolae, little attention has been directed to the biological consequences of cholesterol enrichment of cell membranes and the formation of cholesterol domains. Elevated blood cholesterol levels have been shown to result in the enrichment of the cell plasma membrane with cholesterol in arterial smooth muscle cells (SMC), endothelial cells (EC) and cardiac myocytes. In the early period of cholesterol feeding (within days), the cell membrane enriches with cholesterol and membrane viscosity and membrane bilayer width increase. This latter effect severely alters membrane protein function, and recent data indicates that this induces the modulation of vascular cells (SMC and EC) to the atherosclerotic phenotype. In cardiac myocytes these membrane modifications appear to induce alterations in gene expression patterns that lead to the development of a heart failure phenotype. In addition, as the cholesterol content increases, phase separation of cholesterol occurs resulting in the formation of immiscible cholesterol domains within the membrane. These domains likely initiate nucleation of cholesterol crystals which would explain the origin of "cholesterol clefts" in atherosclerotic lesions. Taken together, these membrane alterations secondary to cholesterol enrichment constitute a "membrane lesion" which contribute to the very early pathogenic events underlying major human diseases including coronary artery disease, stroke and heart failure.
引用
收藏
页码:25 / 38
页数:14
相关论文
共 50 条
  • [41] Fasting Remnant Cholesterol Levels Predict Incident Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease: The ACCELERATE Trial
    Ruotolo, Giacomo
    Lincoff, Michael A.
    Menon, Venu
    McErlean, Ellen
    Wolski, Kathy
    Weerakkody, Govinda
    Riesmeyer, Jeffrey S.
    Nissen, Steven E.
    Nicholls, Stephen J.
    CIRCULATION, 2017, 136
  • [42] Codetermination of Sphingomyelin and Cholesterol in Cellular Plasma Membrane in Sphingomyelin-Depletion-Induced Cholesterol Efflux
    Huang, Shuohan
    Liu, Kang
    Jiang, Dechen
    Fang, Danjun
    ANALYTICAL CHEMISTRY, 2019, 91 (02) : 1501 - 1506
  • [43] Membrane Cholesterol Is a Biomechanical Regulator of Neutrophil Adhesion
    Oh, Hana
    Mohler, Emile R., III
    Tian, Aiwei
    Baumgart, Tobias
    Diamond, Scott L.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (09) : 1290 - 1297
  • [44] High-density lipoprotein-cholesterol, reverse cholesterol transport, and cardiovascular risk: a tale of genetics?
    Cimmino, Giovanni
    D'Amico, Chiara
    Ciccarelli, Giovanni
    Golino, Marco
    Morello, Alberto
    D'Elia, Saverio
    Marchese, Valeria
    Golino, Paolo
    CARDIOGENETICS, 2013, 3 (01) : 38 - 43
  • [45] HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients
    Silbernagel, Guenther
    Genser, Bernd
    Drechsler, Christiane
    Scharnagl, Hubert
    Grammer, Tanja B.
    Stojakovic, Tatjana
    Krane, Vera
    Ritz, Eberhard
    Wanner, Christoph
    Maerz, Winfried
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (02): : 484 - 492
  • [46] Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease
    de Fost, M.
    Langeveld, M.
    Franssen, R.
    Hutten, B. A.
    Groener, J. E. M.
    de Groot, E.
    Mannens, M. M.
    Bikker, H.
    Aerts, J. M. F. G.
    Kastelein, J. J. P.
    Hollak, C. E. M.
    ATHEROSCLEROSIS, 2009, 204 (01) : 267 - 272
  • [47] Hyperlipidaemia and IFNgamma/TNFalpha Synergism are associated with cholesterol crystal formation in Endothelial cells partly through modulation of Lysosomal pH and Cholesterol homeostasis
    Baumer, Yvonne
    Dey, Amit K.
    Gutierrez-Huerta, Cristhian A.
    Khalil, Noor O.
    Sekine, Yusuke
    Sanda, Gregory E.
    Zhuang, Jie
    Saxena, Ankit
    Stempinski, Erin
    Elnabawi, Youssef A.
    Dagur, Pradeep K.
    Ng, Qimin
    Teague, Heather L.
    Keel, Andrew
    Rodante, Justin A.
    Boisvert, William A.
    Tsoi, Lam C.
    Gudjonsson, Johann E.
    Bleck, Christopher K. E.
    Chen, Marcus Y.
    Bluemke, David A.
    Gelfand, Joel M.
    Schwartz, Daniella M.
    Kruth, Howard S.
    Powell-Wiley, Tiffany M.
    Playford, Martin P.
    Mehta, Nehal N.
    EBIOMEDICINE, 2020, 59
  • [48] HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
    Rohatgi, Anand
    Khera, Amit
    Berry, Jarett D.
    Givens, Edward G.
    Ayers, Colby R.
    Wedin, Kyle E.
    Neeland, Ian J.
    Yuhanna, Ivan S.
    Rader, Daniel R.
    de Lemos, James A.
    Shaul, Philip W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (25) : 2383 - 2393
  • [49] Trajectory of low-density lipoprotein cholesterol in patients with chronic kidney disease and its association with cardiovascular disease
    Wang, Shih-Wei
    Li, Lung-Chih
    Fu, Chung-Ming
    Lee, Yueh-Ting
    Kuo, Hsiao-Ching
    Hsu, Chien-Ning
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [50] Transintestinal cholesterol excretion in health and disease
    Garcon, Damien
    Berger, Jean-Matthieu
    Cariou, Bertrand
    Le May, Cedric
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (03) : 153 - 160